Skip to main content
. Author manuscript; available in PMC: 2017 Jun 7.
Published in final edited form as: Peptides. 2015 Oct 31;75:8–17. doi: 10.1016/j.peptides.2015.10.007

Figure 2.

Figure 2

Comparison of the ability of four chiral diazepine analogs (3F, 9D, 9F, 9G); a nonselective Bn analog agonist (Peptide #1); a nonpeptide agonist MK-5046; GRP and NMB to inhibit binding to cells containing human, rat or mouse GRPR. The peptides were incubated with 50 pM 125I- [D-Tyr6, β-Ala11, Phe13, Nle14]Bn-(6–14) for 60 minutes at 21°C in 300 μl of binding buffer with hGRPR/BALB cells (0.5 x 106 cells/ml) (A), rGRPR/AR42J cells (1 x 106 cells/ml) (B) or mGRPR/BALB cells (0.5 x 106 cells/ml) (C), and the saturable binding was determined as described under Materials and Methods. The results are expressed as the percentage of saturable binding without unlabeled peptide added (percentage control). The results are the mean and S.E.M. from at least three separate experiments and in each experiment the data points were determined in duplicated. Abbreviations: See in table 1 legend.